Example: Heart Attack

Clinical Trials on Microsatellite Instability

Total 79 results

NCT03447431

Recruiting

Aberrant Splicings Due to Microsatellite Instability in Colorectal Cancer : Physiopathological and Clinical Impact

Conditions: Colorectal Cancer; Microsatellite Instability
NCT04817826

Not yet recruiting

TremelImumab aNd Durvalumab For the Non-operatIve Management (NOM) of MSI-high Resectable GC/GEJC.

Conditions: Gastric Cancer; Microsatellite Instability
NCT03594448

Recruiting

Detection of MSI in Circulating Tumor DNA of Colorectal Carcinoma Patients

Conditions: Microsatellite Instability; Colorectal Cancer Stage IV
NCT03561350

Unknown status

Detect Microsatellite Instability Status in Blood Sample of Advanced Colorectal Cancer Patients by Next-Generation Sequencing

Conditions: Colorectal Neoplasms
NCT04482608

Completed

The mCRC Patients With pMMR/MSS or dMMR/MSI-H Status Received Palliative Chemotherapy Efficacy and Survival

Conditions: Colorectal Cancer Metastatic; Mismatch Repair Deficiency; Microsatellite Instability High
NCT03485196

Recruiting

The Relationship Between Microsatellite Instability and Efficacy of Fluorouracil Based Adjuvant Chemotherapy in Gastric Cancer After Operation

Conditions: Gastric Cancer
NCT04001101

Recruiting

Anti-PD-1 +/- RT for MSI-H Solid Tumors

Conditions: Microsatellite Instability High; Mismatch Repair Deficiency; Colorectal Cancer
NCT04232020

Completed

A Retrospective Validations Microsatellite Instability (MSI) Testing v Mismatch Repair (MMR) in Gastric Adenocarcinoma

Conditions: Gastric Cancer
NCT04258111

Active, not recruiting

IBI310 in Combination With Sintilimab in Patients With DNA Mismatch Repair Deficient(dMMR)/Microsatellite Instability High (MSI-H)Locally-advanced or Metastatic Colorectal Cancer

Conditions: Colorectal Cancer
NCT04008030

Recruiting

A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)

Conditions: Metastatic Colorectal Cancer
NCT04006262

Recruiting

Peri-operative Association of Immunotherapy (Pre-operative Association of Nivolumab and Ipilimumab, Post-operative Nivolumab Alone) in Localized Microsatellite Instability (MSI) and/or Deficient Mismatch Repair (dMMR) Oeso-gastric Adenocarcinoma

Conditions: Localized Oesogastric Adenocarcimona; MSI and or dMMR
NCT03436563

Recruiting

M7824 in Patients With Metastatic Colorectal Cancer or With Advanced Solid Tumors With Microsatellite Instability

Conditions: Colon Adenocarcinoma; High-Frequency Microsatellite Instability; Metastatic Malignant Solid Neoplasm; Rectal Adenocarcinoma; Refractory Colorectal Carcinoma; Stage IV Colon Cancer AJCC v8; Stage IV Rectal Cancer AJCC v8; Stage IVA Colon Cancer AJCC v8; Stage IVA Rectal Cancer AJCC v8; Stage IVB Colon Cancer AJCC v8; Stage IVB Rectal Cancer AJCC v8
NCT03519412

Recruiting

Pembrolizumab in MMR-Proficient Metastatic Colorectal Cancer Pharmacologically Primed to Trigger Hypermutation Status

Conditions: Colorectal Neoplasms; Microsatellite Instability
NCT04715633

Recruiting

PD-1 Inhibitors Combined With VEGF Inhibitors for Locally Advanced dMMR/MSI-H Colorectal Cancer

Conditions: Colorectal Cancer; Microsatellite Instability High
NCT02563002

Active, not recruiting

Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK-3475-177/KEYNOTE-177)

Conditions: Colorectal Carcinoma
NCT03926338

Recruiting

Toripalimab With or Without Celecoxib as Neoadjuvant Therapy in Resectable dMMR/MSI-H Colorectal Cancer

Conditions: Colorectal Cancer; Mismatch Repair-deficient (dMMR); Microsatellite Instability-high (MSI-H); Neoadjuvant Therapy
NCT03744962

Unknown status

MSI in Circulatory DNA of Endometrial Cancer

Conditions: Microsatellite Instability; Lynch Syndrome; Endometrial Cancer; Circulating Tumor Cell
NCT03827044

Active, not recruiting

Avelumab Plus 5-FU Based Chemotherapy as Adjuvant Treatment for Stage 3 MSI-High or POLE Mutant Colon Cancer

Conditions: POLE Exonuclease Mutant Colon Cancer; Microsatellite Instability; Stage III Colon Cancer
NCT02966587

Withdrawn

Durvalumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

Conditions: Castration Levels of Testosterone; Hormone-Resistant Prostate Cancer; Microsatellite Instability
NCT02887365

Unknown status

A Phase II Study of Tegafur-Uracil as Maintenance Chemotherapy in Patients With Stage II of Colon Cancer

Conditions: MSI-L/MSS; Stage II Colon Cancer
NCT01876511

Completed

Study of MK-3475 in Patients With Microsatellite Unstable (MSI) Tumors (Cohorts A, B and C)

Conditions: MSI Positive Colorectal Cancer; MSI Negative Colorectal Cancer; MSI Positive Non-Colorectal Cancers
NCT00952874

Completed

Molecular Biology of Anal Cancer in HIV-Positive Patients

Conditions: Carcinoma; HIV Infections
NCT03836352

Recruiting

Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors

Conditions: Ovarian Cancer; Hepatocellular Carcinoma; Non-small Cell Lung Cancer; Bladder Cancer; Microsatellite Instability-High
NCT03053466

Recruiting

APL-501 Study for Select Advanced or Relapsed/Recurrent Solid Tumors

Conditions: Solid Tumor; Microsatellite Instability; Mismatch Repair Deficiency; Cancer of Unknown Primary Site
NCT03495674

Active, not recruiting

Cycling in Preventing Colorectal Cancer in Participants With Lynch Syndrome

Conditions: High-Frequency Microsatellite Instability; Mismatch Repair Gene Mutation; Mutation-Negative Lynch Syndrome; Mutation-Positive Lynch Syndrome